Systems approach to rational combination therapy: PARP inhibitors

Abstract excerpt

Poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated activity across a broad spectrum of molecular backgrounds and tumor types, with the greatest activity observed in patients with aberrations in the homologous recombination DNA damage repair pathway. Despite remarkable responses in a subset of patients, the response is usually modest and transient due to the almost inevitable emergence of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Integrated Circuits and Semiconductor Failure Analysis
• Share to PARP inhibition in cancer therapy